

Supporting Information

Nakamura et al. 10.1073/pnas.1300140110

SI Materials and Methods

Natural Killer Cytotoxicity Assay. Natural killer (NK) cytotoxicity assay was performed as previously described (1). In brief, target cells were labeled with $\text{Na}_2^{51}\text{CrO}_4$ (PerkinElmer) at 37 °C for 1 h. Then, target cells were incubated with effector cells in 96-well round-bottom plates at indicated effector/target (E/T) ratios for 4 h. The percentage of specific ^{51}Cr release was calculated as follows: $100 \times (\text{experimental lysis} - \text{spontaneous lysis}) / (\text{maximal lysis} - \text{spontaneous lysis})$.

In Vitro NK Cell Death Assay. IL-2-activated NK cells (1×10^5 per well) were labeled with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) (1 μM ; Invitrogen), and then cocultured with target cells in indicated effector/target (E/T) ratios in 96-well round-bottom plates for 2 h at 37 °C. After coculture, cells were stained with anti-NK1.1 mAb (PK136; BioLegend) and propidium iodide (PI; Sigma). The percentage of PI-positive cells within the CFSE⁺ NK1.1⁺ population was measured on a FACSCanto II (BD Biosciences). For blocking assays, NK cells were pretreated with anti-CD16/CD32 mAb (2.4G2, 10 $\mu\text{g}/\text{mL}$; BD), and then incubated with the following mAb (10 $\mu\text{g}/\text{mL}$) for 30 min before coculture: anti-natural killer type 2 group D (NKG2D) (CX5; generated as previously described) (2), anti-Fas ligand (FasL) (Kay-10; BioLegend), anti-TNF-related apoptosis-inducing ligand (TRAIL) (N2B2; BioLegend), and anti-DNAX accessory molecule 1 (DNAM-1) (10E5; BioLegend).

In Vivo NK Cell Death Assay. CFSE-labeled wild type (WT) C57BL/6 NK cells (5×10^6) were cocultured with RMA or RMA stably expressing retinoic acid early inducible protein 1 δ (RMA/Rae-1 δ) (5×10^6 each) for 15 min, and these cells were injected into spleen of recombination activating gene-1-deficient (Rag-1^{-/-}) mice ($n = 4$ each). After 4 h, splenocytes were stained with anti-NK1.1 mAb, and the percentage of CFSE⁺ NK1.1⁺ cells in whole splenocytes was calculated. To address the contribution of host NK cells to adoptively transferred NK cell death, CFSE-labeled NK1.1-negative BALB/c NK cells (5×10^6) cocultured with RMA or RMA/Rae-1 δ (5×10^6 each) were injected into spleen of WT C57BL/6 mice or NK-depleted C57BL/6 mice that had been intraperitoneally injected with anti-NK1.1 mAb (250 $\mu\text{g}/\text{mouse}$) 4 d before the adoptive transfer. At 4 h after the transfer, splenocytes were stained with anti-H-2K^d mAb (SF1-1.1; BioLegend), and the percentage of CFSE⁺ H-2K^{d+} cells in whole splenocytes was calculated.

Stimulation of NKG2D Receptor. Anti-NKG2D mAb (CX5) or control rat IgG were immobilized on 96-well flat-bottom plates by DOTAP (Sigma) at 10 $\mu\text{g}/\text{mL}$ as previously described (3). IL-2-activated NK cells (2×10^5 per well) pretreated with anti-CD16/CD32 mAb (2.4G2) were then added onto coated plates and cultured in growth medium with recombinant human IL-2 (100 units/mL) for the indicated periods. Then, NK cells were collected and cell death was analyzed by flow cytometry using PI. The amount of IFN- γ in the culture supernatants was determined with the mouse IFN- γ Femto-HS high-sensitivity ELISA kit (eBioscience), according to the manufacturer's instructions.

In Vitro Trogocytosis Assay. CFSE-labeled, IL-2-activated NK cells (1×10^5 per well) and target cells (1×10^5 per well) were cocultured in 96-well plates for indicated periods at 37 °C. Cells were pretreated with anti-CD16/CD32 mAb (2.4G2), and then

stained with allophycocyanin (APC)-conjugated pan-specific Rae-1 mAb (186107; R&D Systems). For the blocking assay using mAb, Fc-blocked cells were pretreated with the following mAb (10 $\mu\text{g}/\text{mL}$) before coculture: anti-NKG2D (CX5), anti-intercellular adhesion molecule-1 (ICAM-1) (KAT-1; eBioscience), anti-CD48 (HM48-1; BioLegend), and anti-2B4 [m2B4 (B6)4458.1; BioLegend]. IgG from rat serum (Sigma) was used as the control antibody. For blocking assays using chemical inhibitors, NK cells were incubated with the following reagents for 30 min before coculture: spleen tyrosine kinase (Syk) inhibitor piceatannol (12.5–100 μM ; Wako), PI3-kinase inhibitor LY294002 (12.5–100 μM ; Wako), mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 (12.5–50 μM ; Wako), Src family kinase inhibitor PP2 (12.5–50 μM ; Wako), actin polymerization inhibitor cytochalasin D (20 μM ; Sigma), an inhibitor of clathrin-dependent endocytosis chlorpromazine (10 $\mu\text{g}/\text{mL}$; Sigma), an inhibitor of caveolae-dependent endocytosis filipin complex (2 $\mu\text{g}/\text{mL}$; Sigma), and broad endocytosis inhibitor methyl- β cyclodextrin (10 mM; Sigma). For some assays, NK cells were cultured in the hypertonic media containing 0.45 M sucrose (Wako), which inhibits clathrin-dependent endocytosis as described previously (2).

In Vivo Trogocytosis Assay. RMA-S (5×10^5), RMA/Rae-1 δ (1×10^6), B16 (5×10^5), or B16/Rae-1 ϵ (2×10^6) were injected s.c. into WT C57BL/6 mice. Tumor tissues were collected at 2 wk after transplantation and treated with collagenase (200 units/mL, Wako). Tumor-infiltrating lymphocytes were stained with anti-DX5 mAb, and anti-Rae-1 mAb, and Rae-1 expression on DX5⁺ cells was analyzed by flow cytometry. As the other model, RMA or RMA/Rae-1 δ (1×10^7 each) were injected into spleen of Rag-1^{-/-} mice. After 2 h, splenocytes were collected and stained with anti-NK1.1 mAb (PK136; BioLegend) and anti-Rae-1 mAb (R&D Systems). Rae-1 expression on NK1.1⁺ cells was analyzed by flow cytometry.

Human NK Trogocytosis Assay. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Separate-L (Muto Pure Chemicals) from healthy donors. Mouse pro B-cell line Ba/F3 cells stably expressing a human NKG2D ligand, MHC class I chain-related molecules A (Ba/F3-MICA) was prepared as previously described (2). PBMC were cocultured with Ba/F3-MICA at a 1:1 ratio for 1 h. PBMCs were also cultured with naturally processed soluble MICA (2,000 pg/mL) for 24 h. Then, cells were stained with anti-CD3 mAb (UCHT1, BioLegend), anti-CD56 mAb (HCD56, BioLegend), and anti-MICA/B mAb (6D4, BioLegend). As for the soluble MICA, the supernatant of confluent cultured BaF3-MICA was harvested, and the concentration was determined by ELISA using Human MICA Duoset (R&D Systems).

RT-PCR. Total RNA was purified from NK cells using Sepasol (Nacalai). Complementary DNAs were synthesized from total RNAs by using oligo(dT) primer (Invitrogen). PCR was performed by using 10-fold serially diluted cDNA templates, AmpliTaq poly (Applied Biosystems). Primer for amplifying *Raet1e* (forward primer 5'-AGA CCT TCC CTG GTG TGA CGT G-3' and reverse primer 5'-TGT CTG CAT TGG GGT ATG AA-3') and *Actb* (forward primer 5'-TCC CTG GGG CAG AGT GGT GAA GAT-3' and reverse primer 5'-ATG GAT GAC GAT ATC GCT GCG CTG-3') were used.

